BBOT

Conviction 55HealthcareScan · Mon, Aug 10, 2026

BBOT$9.28-0.59%

ResistanceSupportVol 14

Vol MA14 252.19K

May 11May 28Jun 16Jul 6Jul 23Aug 10

BridgeBio Oncology Therapeutics, Inc.PHARMACEUTICAL PREPARATIONSwww.bridgebio.com ↗

Price9.28

Change-0.59%

Gap-0.43%

Rel volume0.29×

Avg volume283.69K

Avg $ vol2.45M

SMA 208.67

SMA 508.24

SMA 20010.06

Price vs 50+12.57%

Price vs 200-7.79%

MA stackmixed

50/200 cross—

Supertrendup · 7.85

RSI (14)60

MACD hist0.06

MACD crossbull · 3d

Stoch %K / %D81 / 77

ADX (14)17

+DI / −DI25 / 13

RSI divergence—

MACD divergence—

ATR %+5.73%

ADR %6.06%

52w high13.73

52w low7.12

From 52w high-32.45%

Above 52w low+30.27%

New 52w highNo

SqueezeOn · 11d

Bollinger width14.80%

%B0.98

Donchian pos81.96%

Donchian high9.57

Donchian low7.94

AVWAP (52w high)9.44

vs AVWAP high-1.70%

AVWAP (52w low)8.15

vs AVWAP low+13.75%

OBV trendFlat

Chaikin MF (20)-0.04

Today vs 20d0.29×

Avg vol (14d)252.19K

Avg vol (20d)283.69K

Avg $ vol (20d)2.45M

Market cap742.99M

RS 3m (vs SPY)+13.01%

RS 6m (vs SPY)-22.19%

RS line new highNo

Trend template—

Technical rank45.9

1 week+12.42%

1 month+11.48%

3 months+21.08%

6 months-13.32%

1 year—

YTD-24.53%

P/E-5.54

P/B2.00

P/S—

P/FCF-6.49

EPS-4.30

Div yield—

ROE-36.01%

ROA-32.10%

Debt/Eq—

Current6.16

EV/EBITDA—

Gross margin—

Net margin—

Rev growth—

EPS growth-80.47%

Price target—

Target upside—

Analyst rating—

Institutional—

Ent. value690.34M

Revenue—

Net income-42.11M

Gross profit—

Free cash flow-114.5M

IndustryPHARMACEUTICAL PREPARATIONS

ExchangeNasdaq

Shares out80.11M

Employees106

ListedTue, Aug 12, 2025

Free float42.42M

Float %53.0%

Short interest5.69M

Days to cover12.6d

Short volume61.7%

Squeeze score66 / 100

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeC

Conviction55 / 100

Pattern quality—

Tech rank45.9 / 100

Group rank86 / 100 · Leading

Status laneNo active setup

Setup direction—

Pattern family

Resistance9.41

Support7.30

Days since event—

Candle confirm—

News sentiment—

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in BBOT

All disclosures →

No recent disclosed trades by Congress in BBOT. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in BBOT · 9 buys · 1 sell

Insider	Side	Shares	Value	Traded	Filed
Bauer Jake Director · Stock Option (Right to Buy) · 2026-06-16	Grant	31.68K	—	2026-06-16	2026-06-18
Kumar Neil Director · Stock Option (Right to Buy) · 2026-06-16	Grant	31.68K	—	2026-06-16	2026-06-18
Chen Bihua Director · Stock Option (Right to Buy) · 2026-06-16	Grant	31.68K	—	2026-06-16	2026-06-18
Kelleher Raymond J. Director · Stock Option (Right to Buy) · 2026-06-16	Grant	31.68K	—	2026-06-16	2026-06-18
Lebowitz Peter F Director · Stock Option (Right to Buy) · 2026-06-16	Grant	7.29K	—	2026-06-16	2026-06-18
MCCORMICK FRANK Director · Stock Option (Right to Buy) · 2026-06-16	Grant	31.68K	—	2026-06-16	2026-06-18
Tipirneni Praveen P. Director · Stock Option (Right to Buy) · 2026-06-16	Grant	31.68K	—	2026-06-16	2026-06-18
Elmelech Idan COO & Principal Financial Ofcr · Stock Option (Right to Buy) · 2026-05-10	Grant	758.22K	$0	2026-05-10	2026-05-12
Beltran Pedro President and CEO · Stock Option (Right to Buy) · 2026-05-10	Grant	1.1M	$0	2026-05-10	2026-05-12
Beltran Pedro President and CEO · Common Stock · 2026-04-01	Tax	1.05K	$9K	2026-04-01	2026-05-05

SEC filings

EDGAR filings in BBOT · 3 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.